Insights on the use of biosimilars in the treatment of inflammatory bowel disease

World Journal of Gastroenterology

Volumn 23, Issue 11, 2017, Pages 1932-1943

  Zheng, Michael K ^a   Shih, David Q ^a   Chen, Gary C ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b Gastroenterology and Hepatology   (United States)

Author keywords

Biologic; Biosimilar; Crohn's disease; Indication extrapolation; Inflammatory bowel disease; Interchangeability; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ADALIMUMAB ATTO; AZATHIOPRINE; BIOSIMILAR AGENT; BOW 015; INFLIXIMAB; INFLIXIMAB DYYB; METHOTREXATE; MSB 11022; PF 06438179; UNCLASSIFIED DRUG; ZRC 3197; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

BIOLOGICAL THERAPY; CROHN DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; REMISSION; REVIEW; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SUBSTITUTION; ECONOMICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG SUBSTITUTION; HUMANS; INFLAMMATORY BOWEL DISEASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85015756885     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i11.1932     Document Type: Review

References (104)

1. Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics 2008; 2: 763-777 [PMID: 19707457]
2. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001]
3. Loftus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60 [PMID: 11856078]
4. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007; 76: 1323-1330 [PMID: 18019875]
5. Rencz F, Péntek M, Bortlik M, Zagorowicz E, Hlavaty T, ?liwczy?ski A, Diculescu MM, Kupcinskas L, Gecse KB, Gulácsi L, Lakatos PL. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol 2015; 21: 1728-1737 [PMID: 25684937 DOI: 10.3748/wjg.v21.i6.1728]
6. Revers L, Furczon E. An introduction to biologics and biosimilars. Part I: Biologics: What are they and where do they come from? Can Pharm J 2010; 143: 134-139 [DOI: 10.3821/1913-701X-143. 3.134]
7. Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf) 2015; 3: 63-68 [PMID: 25567472 DOI: 10.1093/gastro/gou087]
8. Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7: 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1]
9. Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther 2016; 159: 110-119 [PMID: 26808166 DOI: 10.1016/j.pharmthera.2016.01.001]
10. Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94: e556 [PMID: 25761174 DOI: 10.1097/MD.0000000000000556]
11. Engel T, Kopylov U. Ustekinumab in Crohn's disease: evidence to date and place in therapy. Ther Adv Chronic Dis 2016; 7: 208-214 [PMID: 27433311 DOI: 10.1177/2040622316653306]
12. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015; 12: 537-545 [PMID: 26284562 DOI: 10.1038/nrgastro.2015.135]
13. FDA Approves STELARA® (Ustekinumab) for Treatment of Moderate to Severe Crohn's Disease. CCFA 2016 [cited 2016-11-15]; Available from: URL: http://www.ccfa.org/news/Stelara.html
14. European Medicines Agency. Guideline on similar biological medicinal products. 2014
15. U.S. Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 2015. Available from: URL: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
16. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006; 21 Suppl 5: v4-v8 [PMID: 16959791 DOI: 10.1093/ndt/gfl474]
17. Morrow T, Felcone LH. Defining the difference: What Makes Biologics Unique. Biotechnol Healthc 2004; 1: 24-29 [PMID: 23393437 DOI: 10.1177/2050640615590302]
18. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. Blood 2014; 124: 3191-3196 [PMID: 25298038 DOI: 10.1182/blood-2014-06-583617]
19. European Medicines Agency. Remicade (infliximab). Summary of product Characteristics. Eur Med Agency 2014
20. Remicade Dosing. Janssen Biotech, Inc.2016 [cited 2016-04-02]; Available from: URL: http://www.remicade.com/hcp/crohnsdisease/dosing
21. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies-non-clinical and clinical issues Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies-Non-clinical and Clinical Issues Table of contents. 2014. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219. pdf
22. U.S. Food and Drug Administration. Biologics Price Competition and Innovation Act. 2009 Available from: URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ucm216146.pdf
23. Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum 2015; 44: S2-S8 [DOI: 10.1016/j.semarthrit .2015.04.002]
24. The Arrival of Biosimilar Therapies. Heal Gastroenterol 2016 Available from: URL: http://www.healio.com/gastroenterology/inflammatory-bowel-disease/news/print/healio-gastroenterology/{f37035aa-1129-42cd-beff-eeb8b3b220e5}/the-arrival-ofbiosimilar-therapies
25. Al-Sabbagh A, Olech E, Mcclellan JE, Kirchhoff CF. Development of biosimilars. Semin Arthritis Rheum 2016; 45: S11-S118 [DOI: 10.1016/j.semarthrit.2016.01.002]
26. Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits 2013; 6: 469-478 [PMID: 24991376 DOI: 10.1016/S1574-0676(06)01021-0]
27. Lehman B. The Pharmaceutical Industry and the Patent System. 2003: 1-14 Available from: URL: http://users.wfu.edu/mcfallta/DiR0/pharma-patents.pdf
28. U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade. 2016 Available from: URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm
29. Amgen. FDA Approves Amgen's AMJEVITA (Adalimumab-Atto) For Treatment of Seven Inflammatory Diseases. 2016 Available from: URL: http://www.amgen.com/media/news-releases/2016/09/fda-approves-amgens-amjevita-adalimumabatto-for-treatment-ofseven-inflammatory-diseases/
30. Shih DQ, Targan SR. Insights into IBD Pathogenesis. Curr Gastroenterol Rep 2009; 11: 473-480 [PMID: 19903423 DOI: 10.1007/s11894-009-0072-9]
31. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-646 [PMID: 22357456 DOI: 10.1038/clpt.2011.328]
32. Teillaud JL. Antibody-dependent Cellular Cytotoxicity (ADCC). In: eLS. Chichester, UK: John Wiley & Sons, Ltd; 2012. Available from: URL: http://doi.wiley.com/10.1002/9780470015902. a0000498.pub2
33. Pierri CL, Bossis F, Punzi G, De Grassi A, Cetrone M, Parisi G, Tricarico D. Molecular modeling of antibodies for the treatment of TNF?-related immunological diseases. Pharmacol Res Perspect 2016; 4: e00197 [PMID: 26977294 DOI: 10.1002/prp2.197]
34. Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, Zou G, Xu Z, Shankar G, Sealey DC, Russell AS. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42: 177-183 [PMID: 24962198 DOI: 10.1016/j.biologicals.2 014.05.005]
35. European Medicines Agency. EPAR summary for the public: Remsima. 2013 Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary-for-the-public/human/002576/WC500150872.pdf
36. Le J. Overview of Pharmacokinetics. Merck Man 2016 Available from: URL: http://www.merckmanuals.com/professional/clinicalpharmacology/pharmacokinetics/overview-of-pharmacokinetics
37. Zhao L, Ren TH, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin 2012; 33: 1339-1347 [PMID: 23001474 DOI: 10.1038/aps.2012.51]
38. Park W, Lee SJ, Yun J, Yoo DH. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, doubleblind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol 2015; 11 Suppl 1: S25-S31 [PMID: 26395834 DOI: 10.1586/1744666X.2015.1090311]
39. Kuhlmann MK, Goldsmith D, Covic A. Biosimilars. Int J Pharm Med 2007; 21: 199-206 [DOI: 10.2165/00124363-200721030-000 02]
40. Bendtzen K. Immunogenicity of Anti-TNF-? Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence. Front Immunol 2015; 6: 152 [PMID: 25904915 DOI: 10.3389/fimmu.2015.00152]
41. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-462 [PMID: 12119747 DOI: 10.1038/nrd818]
42. Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20: 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475]
43. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395 [PMID: 20393175]
44. Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.e3 [PMID: 24512909 DOI: 10.1053/j.gastro.2013.10.052]
45. Feagan BG, McDonald JW, Panaccione R, Enns RA, Bernstein CN, Ponich TP, Bourdages R, Macintosh DG, Dallaire C, Cohen A, Fedorak RN, Paré P, Bitton A, Saibil F, Anderson F, Donner A, Wong CJ, Zou G, Vandervoort MK, Hopkins M, Greenberg GR. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014; 146: 681-688.e1 [PMID: 24269926 DOI: 10.1053/j.gastro.2013.11.024]
46. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B, Smiyan S, Kim H, Lee SJ, Kim S, Park W. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 2017; 76: 355-363 [PMID: 27130908 DOI: 10.1136/annrheumdis-2015-208786]
47. Observations on Trends in Prescription Drug Spending. ASPE Issue Br 2016 1-16 Available from: URL: https://aspe.hhs.gov/sites/default/files/pdf/187586/Drugspending.pdf
48. Abo T. [Inflammatory bowel diseases]. Nihon Rinsho 2004; 62 Suppl 5: 540-544 [PMID: 15197980]
49. Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med 2008; 50: 1261-1272 [PMID: 19001952 DOI: 10.1097/JOM.0b013e318181b8ca]
50. Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther 2015; 32: 742-756 [PMID: 26343027 DOI: 10.1007/s12325-015-0233-1]
51. Brodszky V, Baji P, Balogh O, Péntek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 Suppl 1: S65-S71 [PMID: 24832837 DOI: 10.1007/s10198-014-0595-3]
52. IMS Institute for Healthcare Informatics. Shaping the biosimilars opportunity: A global perspective on the evolving biosimilars landscape. IMS Heal 2011; 1-7 Available from: URL: http://weinberggroup.com/pdfs/Shaping-the-biosimiliars-opportu nity-A-global-perspective-on-the-evolving-biosimiliars-landsca pe.pdf
53. U.S. Food and Drug Administration. FDA approves first biosimilar product Zarxio. 2015 Available from: URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm
54. Fuhr JP. Biosimilars Can Save Lives And Cost Less. Forbes 2014 Available from: URL: http://www.forbes.com/sites/realspin/2014/08/08/biosimilars-can-save-lives-and-cost-less/#149e456d3b2f
55. Miller S. The 250 Billion Potential of Biosimilars. Express Scripts 2013: 1-3 Available from: URL: http://lab.expressscripts. com/speciality-medications/the-250-billion-potential-ofbiosimilars/n
56. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198-206 [PMID: 23467636 DOI: 10.1136/annrheumdis-2012-202603]
57. Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A Multidisciplinary Perspective. Clin Ther 2016; 38: 1238-1249 [PMID: 26988243 DOI: 10.1016/j.clinthera.2016.02.023]
58. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094 [PMID: 11677200 DOI: 10.1053/gast.2001.28674]
59. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785 [PMID: 12806611 DOI: 10.1016/S0016-5085(03)00382-2]
60. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003; 48: 2155-2162 [PMID: 12905468 DOI: 10.1002/art.11098]
61. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-1612 [PMID: 23687259 DOI: 10.1136/annrheumdis-2012-203091]
62. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, Kovalenko V, Prodanovic N, Abello-Banfi M, Gutierrez-Ureña S, Morales-Olazabal L, Tee M, Jimenez R, Zamani O, Lee SJ, Kim H, Park W, Müller-Ladner U. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-1620 [PMID: 23687260 DOI: 10.1136/annrheumdis-2012-203090]
63. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, Sariego IG, Abud-Mendoza C, Escalante WJ, Kang SW, Andersone D, Blanco F, Hong SS, Lee SH, Braun J. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther 2016; 18: 25 [PMID: 26795209 DOI: 10.1186/s13075-016-0930-4]
64. Summary Basis of Decision (SBD): Remsima. Heal Canada 2015 Available from: URL: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2014-remsima-160195-eng.php
65. U.S. Food and Drug Administration. Arthritis Advisory Committee Meeting: CT-P13. 2016 Available from: URL: http://www.fda. gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM484859.pdf
66. World Health Organization (WHO). Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009: 19-23 Available from: URL: http://www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22AP RIL2010.pdf
67. Biosimilar switching not suitable for all patients. London, United Kingdom: 2016 Available from: URL: http://www.eular. org/congresspressreleases/Biosimilar- switching-not-suitable- for-all-patients---OP0015.pdf
68. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54 [PMID: 19651627 DOI: 10.1136/gut.2009.183095]
69. PR Newswire. Prometheus Diagnostic Test Validated in Anticipation of U.S. Healthcare Provider Demand for Celltrion's INFLECTRATM (Biosimilar Infliximab). 2016 Available from: URL: http://www.prnewswire.com/news-releases/prometheusdiagnostic-test-validated-in-anticipation-of-us-healthcare-provider-demand-for-celltrions-inflectra-biosimilar-infliximab-300248068. html
70. Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care 2015; 21: s331-s340 [PMID: 26788809 DOI: 10.2139/ssrn.779005]
71. Warren WL, Fang L, Goron K. Abbreviated approval of generic biologics. Genet Eng News 2006; 26: 9-10 Available from: URL: http://www.sutherland.com/portalresource/lookup/poid/Z1tOl9NPluKPtDNIqLMRV56Pab6TfzcRXnc KbDtRr9tObDdEuSpCp0!/fileUpload.name=/UPDATEDGEN legal-warren-final21.pdf
72. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals (Basel) 2012; 5: 353-368 [PMID: 24281406 DOI: 10.3390/ph5040353]
73. Mulcahy A, Predmore Z, Mattke S, States U. The Cost Savings Potential of Biosimilar Drugs in the United States. RAND Corp 2014 Available from: URL: https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND-PE127.pdf
74. U.S. Food and Drug Administration. Information for Healthcare Professionals (Biosimilars). U.S. Dep Heal Hum Serv 2015. Available from: URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedand Approved/ApprovalApplications/TherapeuticBiologic Applications/Biosimilars/ucm241719.htm
75. Blackstone EA, Fuhr JP. Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety. Biotechnol Healthc 2012; 9: 24-27 [PMID: 22606078 DOI: 10.1111/j.1468-5876.2008.00466.x]
76. Cauchi R. State Laws and Legislation Related to Biologic Medications and Substitution of Biosimilars. Natl Conf State Legis 2016 Available from: URL: http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-andsubstitution-of-biosimilars.aspx
77. Reinisch W, Smolen J. Biosimilar safety factors in clinical practice. Semin Arthritis Rheum 2015; 44: S9-S15 [DOI: 10.1016/j.semarthrit.2015.04.005]
78. Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. J Crohns Colitis 2017; 11: 26-34 [PMID: 27927718 DOI: 10.1093/ecco-jcc/jjw198]
79. Aquino JT. FDA Extends Wait for Biosimilar Interchangeability Guidance. Bloom. BNA 2016 Available from: URL: http://www. bna.com/fda-extends-wait-n57982077557/
80. European Medicines Agency. European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. 2013 Available from: URL: http://www.ema.europa. eu/ema/index.jsp?curl=pages/news-and-events/news/2013/06/news-detail-001837.jsp&mid=WC0b01ac058004d5c1
81. Murphy C, Sugrue K, Mohamad G, McCarthy J, Buckley M. P505. Biosimilar but not the same. J Crohns Colitis 2015; 9: S331-S332 [DOI: 10.1093/ecco-jcc/jju027.623]
82. Jung YS, Park Di, Kim YH, Lee JH, Seo PJ, Cheon JH, Kang HW, Kim JW. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol 2015; 30: 1705-1712 [PMID: 25974251 DOI: 10.1111/jgh.12997]
83. Celltrion Healthcare: Patients feel the benefit of biosimilar infliximab in Europe. Bus Wire 2015 Available from: URL: http://www.businesswire.com/news/home/20150518006521/en/Celltrion-Healthcare-Patients-feel-benefit-biosimilar-infliximab
84. Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol 2015; 9 Suppl 1: 45-52 [PMID: 26395534 DOI: 10.1586/17474124 .2015.1091308]
85. Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort. J Crohns Colitis 2016; 10: 133-140 [PMID: 26661272 DOI: 10.1093/ecco-jcc/jjv220]
86. Sieczkowska J, Jarzebicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, Kierkus J. Assessment of safety and efficacy of biosimilar infliximab in children with Crohn disease: A preliminary report. J Crohns Colitis 2015; 9: S295
87. Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, Hoentjen F. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. J Crohns Colitis 2016; 10: 1287-1293 [PMID: 27095751 DOI: 10.1093/ecco-jcc/jjw087]
88. The NOR-SWITCH Study (NOR-SWITCH). ClinicalTrials.gov 2015 [cited 2016-03-22]. Available from: URL: https://clinicaltrials. gov/show/NCT02148640
89. Celltrion Healthcare Showcases Data Supporting Efficacy and Safety of Both CT-P10 and CT-P13 Biosimilars. Bus Wire 2016 Available from: URL: http://www.businesswire.com/news/home/20161114005543/en/Celltrion-Healthcare-Showcases-Data-Supporting-Efficacy-Safety
90. Biogen. FLIXABI®, Biogen's Infliximab Biosimilar Referencing Remicade®, Approved in the European Union. 2016 Available from: URL: http://media.biogen.com/press-release/biosimilars/flixabi-biogens-infliximab-biosimilar-referencing-remicadeapproved-europe
91. Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, Yatsyshyn R, Mekic M, Porawska W, Ciferska H, Jedrychowicz-Rosiak K, Zielinska A, Choi J, Rho YH, Smolen JS. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2017; 76: 58-64 [PMID: 26318384 DOI: 10.1136/annrheumdis-2015-207764]
92. Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA. Novartis 2016 Available from: URL: https://www.novartis.com/news/media-releases/sandoz-strengthens-its-biosimilars-portfolio-acquisition-pfizersbiosimilar
93. Udata C, Hua SY, Yin D, Salts S, Meng X, Rehman MI. FRI0301 A Phase I Pharmacokinetics TRIAL Comparing PF-06438179 (A Potential Biosimilar) and Infliximab in Healthy Volunteers (Reflections B537-01). Ann Rheum Dis 2014; 73: 494.1-494 [DOI: 10.1136/annrheumdis-2014-eular.5377]
94. A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02). ClinicalTrials. gov 2016 Available from: URL: https: //clinicaltrials.gov/ct2/show/NCT02222493
95. Rajan C. Epirus's Biosimilar Arthritis Drug Wins Approval in India. Bioprocess Online 2014 Available from: URL: http://www. bioprocessonline.com/doc/epirus-s-biosimilar-arthritis-drug-winsapproval-in-india-0001
96. BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study. ClinicalTrials. gov 2016 Available from: URL: https: //clinicaltrials.gov/ct2/show/NCT02683564
97. PR Newswire. Amgen's First Biosimilar Biologics License Application For ABP 501 Submitted To U.S. Food And Drug Administration. 2015 Available from: URL: http://www. prnewswire.com/news-releases/amgens-first-biosimilar-biologicslicense-application-for-abp-501-submitted-to-us-food-and-drugadministration-300184581.html
98. PR Newswire. Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab. 2015 Available from: URL: http://www.prnewswire.com/news-releases/amgen-presents-detailed-results-from-phase-3-study-demonstrating-clinical-equivalence-ofbiosimilar-candidate-abp-501-with-adalimumab-300175207.html
99. Amgen. Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis. 2014 Available from: URL: http://investors.amgen.com/phoenix.zhtml?c=61656&p=irolnewsArticle&ID=1975377
100. PR Newswire. Zydus Launches World's First Biosimilar of Adalimumab. 2014 Available from: URL: http://www.prnewswire. com/news-releases/zydus-launches-worlds-first-biosimilar-ofadalimumab-285185321.html
101. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, Kumar U, Gauri LA, Jadhav P, Bartakke G, Haridas V, Jain D, Mendiratta SK. A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis 2016; 19: 1157-1168 [PMID: 26176644 DOI: 10.1111/1756-185X.12711]
102. MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (AURIEL-PsO). ClinicalTrials.gov 2016. Available from: URL: https://clinicaltrials.gov/ct2/show/NCT02660580
103. Silver S. Industry Surveys: Biotechnology. New York: 2013. Available from: URL: https://securingalpha.files.wordpress. com/2014/01/biotechnology-2013.pdf
104. Sieczkowska J, Jarz?bicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, Oracz G, Meglicka M, Kierkus J. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations. J Crohns Colitis 2016; 10: 127-132 [PMID: 26721942 DOI: 10.1093/ecco-jcc/jjv233]